Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Osteitis Deformans × Trastuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 208 Stomach Neoplasms 17 Neoplasm Metastasis 13 Breast Neoplasms, Male 13 Neoplasms 8 Esophageal Neoplasms 8 Brain Neoplasms 7 Inflammatory Breast Neoplasms 6 Colorectal Neoplasms 4 Adenocarcinoma Of Esophagus 4 Triple Negative Breast Neoplasms 3 Urologic Neoplasms 2 HER2-positive Breast Cancer 2 Gallbladder Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Carcinoma, Intraductal, Noninfiltrating 2 Carcinoma, Ductal, Breast 2 Adenocarcinoma 2 Urinary Bladder Neoplasms 1 Solid Cancers 1 Rectal Neoplasms 1 Patient Preference 1 Patient Compliance 1 Osteitis Deformans 1 Neoplasm, Residual 1 Meningeal Neoplasms 1 Malignant Solid Neoplasm 1 Locally Advanced Breast Cancer 1 Lethal Congenital Contracture Syndrome 2 1 Hormone Receptor Positive Breast Cancer 1

Interventions

Lapatinib 2 ribociclib 1 Trastuzumab 1 Paclitaxel 1 Letrozole 1 Goserelin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00553358 2021-09-21

Neo ALTTO

Novartis

Phase 3 Completed

455 enrolled 34 charts

Breast Neoplasms, Osteitis Deformans

Data powered by HemOnc (CC BY 4.0) Colophon ⚡